Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Novartis
Novartis
Kivu Bioscience Inc.
Hoffmann-La Roche
Endeavor Biomedicines, Inc.
City of Hope Medical Center
M.D. Anderson Cancer Center
University of California, Irvine
M.D. Anderson Cancer Center
ViroMissile, Inc.
Essen Biotech
MacroGenics
City of Hope Medical Center
Perspective Therapeutics
M.D. Anderson Cancer Center
Ocellaris Pharma, Inc.
Eli Lilly and Company
Var2 Pharmaceuticals
UNICANCER
Memorial Sloan Kettering Cancer Center
Tanabe Pharma America, Inc.
Transgene
HiFiBiO Therapeutics
Tango Therapeutics, Inc.
Bayer
National Institutes of Health Clinical Center (CC)
Actym Therapeutics, Inc.
Hadassah Medical Organization
British Columbia Cancer Agency
Valo Therapeutics Oy
Epkin
Guangzhou FineImmune Biotechnology Co., LTD.
Institut Bergonié
GONGCHU Biotechnology Co., Ltd
Jonsson Comprehensive Cancer Center
Washington University School of Medicine
Turning Point Therapeutics, Inc.
University of Pittsburgh
Telix Pharmaceuticals (Innovations) Pty Limited
PharmaMar
University of California, Irvine
Cancer Research UK
Columbia University
Instituto do Cancer do Estado de São Paulo
Hutchmed
Elevation Oncology
Institut du Cancer de Montpellier - Val d'Aurelle
Stanford University
Intensity Therapeutics, Inc.
Cedars-Sinai Medical Center
Sarcoma Oncology Research Center, LLC